TNFRSF8 and Hodgkins lymphoma: A CD30 × CD3 TandAb (AFM13) is being tested in clinical trials for cutaneous lymphoma (NCT 03192202—recruiting), R/R Hodgkin lymphoma (NCT 02321592 (recruiting and NCT 02665650—completed).